Psigryph Inc. utilizes its patent-pending Nanopect™ nanodelivery system to enhance the bioavailability of bioactive molecules, enabling efficient transport across cell membranes in humans, animals, and plants. The company addresses the challenge of low nutrient absorption by developing products like Cholestello, which supports healthy cholesterol levels through improved nutrient delivery.
Funding
$610K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many bioactive molecules have limited bioavailability due to poor absorption across cell membranes, hindering their effectiveness in delivering health benefits. This challenge affects the efficacy of nutrients, pharmaceuticals, and other biologically active compounds in humans, animals, and plants.
Solution
Psigryph Inc. has developed Nanopect™, a patent-pending nanodelivery system that enhances the bioavailability of bioactive molecules by facilitating their transport across cell membranes. Derived from Montmorency cherries, Nanopect™ encapsulates and delivers nutrients, cannabinoids, and pharmaceuticals, improving their absorption and efficacy. The technology is applicable across various industries, including food and beverage, agriculture, pharmaceuticals, and animal nutrition. Psigryph offers Nanopect™ in both nanoparticle and nanofiber formats, each optimized for different types of bioactive molecules and delivery requirements.
Target Audience
Psigryph's primary customers include companies in the food and beverage, agriculture, pharmaceutical, and animal nutrition industries seeking to improve the bioavailability and efficacy of their products.
Features
- Nanopect™ nanoparticle delivery system for enhanced absorption of nutrients and other bioactive molecules.
- Nanopect™ nanofiber delivery system for efficient delivery of insoluble molecules, including anti-cancer agents.
- All-natural and biodegradable composition derived from Montmorency cherries.
- Demonstrated ability to improve the delivery of anti-cancer agents to drug-resistant cancer cells.
- SlimLiiv™ food powder, a commercialization-ready product with weight control potential and anti-inflammatory properties.